ATHA Energy Discovers Mineralization Within the Angikuni Basin in First Hole at KU Target and Drilling at Lac 50 Deposit Extends Mineralization
- HIGHLIGHTS Completes first two drill holes of its 2025 Angilak Exploration Program comprising ~10,000m of diamond drilling. KU Discovery Target: The maiden drill hole, KU-DD-001 successfully targeted stacked gravity and structural anomalies (Figure 2), intersecting shallow high-grade uranium mineralization as well as numerous zones of lower-grade mineralization throughout the hole.
- 06/24/2025
|
ATHA Completes Ground Geophysics and Commences 2025 Angilak Diamond Drill Exploration Program
- HIGHLIGHTS The 2025 Angilak Exploration Program will comprise ~10,000 m of diamond drilling with two objectives: Lac 50 Deposit - expansion of the footprint of uranium mineralization. Stepping out along strike and at depth from the 2024 Exploration Target (as defined below), which remains open and unconstrained.
- 06/04/2025
|
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
- Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development
- 05/13/2025
|
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
- Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25
- 05/09/2025
|
Athena Gold Closes Oversubscribed Flow-Through Financing
- THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VACAVILLE, CALIFORNIA / ACCESS Newswire / April 28, 2025 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena Gold" or the "Company") is pleased to announce the closing of a non-brokered private placement of flow-through common shares (the "FT Shares") previously announced on April 7, 2025, as amended April 21, 2025 (the "FT Offering"). The Company issued an aggregate of 15,300,000 FT Shares at a price of CDN $0.05 per FT Share for gross proceeds of CDN$765,000, which represents an oversubscription of CDN$265,000 of the originally planned financing.
- 04/28/2025
|
ATHA Energy Announces Closing of Financing for Aggregate Gross Proceeds of $10,000,000
- NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / April 22, 2025 / ATHA Energy Corp. (TSXV:SASK)(FRA:X5U)(OTCQB:SASKF) ("ATHA" or the "Company") is pleased to announce that, further to its press releases dated March 31, 2025 and April 7, 2025, it has completed a fully-subscribed private placement offering of: (i) 16,766,490 flow-though common shares of the Company ("FT Shares") at a price of $0.47 per FT Share; and (ii) 3,475,000 FT Shares that may be immediately resold or donated to registered charities ("Charity FT Shares", and collectively with the FT Shares, the "Offered Shares") at a price of $0.61 per Charity FT Share for aggregate gross proceeds of approximately $10,000,000(the "Offering").
- 04/22/2025
|
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
- Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS)
- 02/27/2025
|
ATHA Energy expands uranium potential at Angilak
- ATHA Energy Corp (TSX-V:SASK, OTCQB:SASKF) revealed that a survey at its Angilak uranium project in Nunavut has expanded the known depth of uranium mineralization at the Lac 50 Deposit to over one kilometer. The survey also identified a new 25-kilometer conductive trend along the western margin of the Angikuni Basin, according to a statement from ATHA.
- 01/15/2025
|
Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct
- Seattle-area biotech company Athira Pharma agreed to pay $4.
- 01/07/2025
|
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND
- BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highlighting target engagement and neuroprotective effects of ATH-1105 in human motor neurons at the Motor Neurone Disease Association's 35th International Symposium on ALS/MND, taking place Dec. 6-8, 2024, in Montreal, Canada.
- 12/06/2024
|
ATHA Energy identifies high-grade uranium mineralization in new outcrops at Angilak
- ATHA Energy Corp (TSX-V:SASK, OTCQB:SASKF) said it has uncovered numerous outcrops hosting high-grade uranium mineralization at Angilak in Nunavut. The surficial mapping program, centered around the Lac 50 Deposit, identified mineralized outcrops between the Lac 48, Lac 50, Lac 52, and Lac 54 trends, according to a statement from ATHA.
- 12/05/2024
|
ATHA Energy reveals updated technical report for Angilak uranium project
- ATHA Energy Corp (TSX-V:SASK, OTCQB:SASKF) has unveiled its updated 2024 technical report for its 100%-owned Angilak uranium project in Nunavut. The third-party updated technical report establishes a baseline Exploration Target for the Lac 50 Deposit of 60.8–98.2 million pounds of U₃O₈ (uranium) with an average grade range of 0.37–0.48% U₃O₈.
- 11/25/2024
|
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
- Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025
- 11/07/2024
|
ATHA Energy appoints seasoned experts to leadership team
- ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has announced the appointment of Erinn Broshko as a non-executive director and Rhéal Assié as chief financial officer, starting November 6. The company said Broshko, a seasoned executive and lawyer, brings more than 25 years of experience in law, business, and leadership, including roles as CEO and executive chairman in biotech and energy services.
- 10/29/2024
|
ATHA Energy and Terra Uranium enter into strategic option agreements on key uranium projects
- ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) announced that it has entered into option agreement with Terra Uranium Ltd (ASX:T92) which allow the two companies to earn significant interest in each other's uranium exploration projects. ATHA has granted Terra Uranium an option to acquire up to 70% interest in its Spire and Horizon properties, together the Spire Horizon projects.
- 10/11/2024
|
ATHA Energy Announces Option Agreements With Terra Uranium for Spire, Horizon, and Pasfield Projects
- VANCOUVER, British Columbia, Oct. 11, 2024 (GLOBE NEWSWIRE) -- ATHA Energy Corp. (CSE: SASK) (FRA: X5U) (OTCQB: SASKF) (“ATHA”) is pleased to announce, in furtherance to its news release from August 20th, 2024 , the Company and Terra Uranium Ltd. (ASX: T92) (“T92”) have executed a definitive option agreement for T92 to earn an option to acquire a 70% interest in ATHA's Spire and Horizon properties (together, the “Spire Horizon Projects”) and a definitive option agreement for ATHA to earn an option to acquire up to a 60% interest in T92's Pasfield Lake property (the “Pasfield Project”).
- 10/11/2024
|
ATHA Energy CEO highlights 2024 growth priorities at TD Securities Nuclear Roundtable
- ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) CEO Troy Boisjoli highlighted the company's aggressive growth strategy and plans for the year ahead in a discussion at the TD Securities Annual Nuclear Fuel Cycle and Next Generation Nuclear Roundtable. ATHA, listed in April 2023, has rapidly expanded its uranium exploration portfolio.
- 10/10/2024
|
ATHA Energy secures entire Lac 50 structural corridor at Angilak uranium project
- ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has expanded its Angilak Project in Nunavut by acquiring the entire Lac 50 structural corridor, along with an additional prospective parallel corridor. Both corridors are linked to the Snowbird Tectonic Zone, a significant crustal structure that extends from the Athabasca Basin to the Angikuni Basin.
- 09/19/2024
|
Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring
- Seattle-based biotech company Athira Pharma is laying off 49 people, or about 70% of its workforce, as part of cost-cutting measures and a restructuring.
- 09/17/2024
|
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
- ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of ALS patients expected in 2025
- 09/17/2024
|
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal
- Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.
- 09/04/2024
|
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks
- On Wednesday, Athira Pharma, Inc. ATHA stock is trading lower after the company released topline results from its Phase 2/3 LIFT-AD clinical trial of fosgonimeton for mild-to-moderate Alzheimer's disease (AD).
- 09/04/2024
|
Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial
- Athira Pharma said on Tuesday its investigative drug failed to meet the main goal in a mid-to-late stage trial in patients with mild-to-moderate Alzheimer's disease.
- 09/03/2024
|
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease
- LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23)
- 09/03/2024
|
ATHA Energy identifies new mineralized trends at Angilak uranium project
- ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) announced it has completed its 2024 Exploration Program at its Angilak uranium project in Nunavut, which hosts the Lac 50 uranium Deposit. The “highly successful” program was carried out from early June to late August and involved 25 diamond drill holes totalling about 10,051 meters.
- 09/03/2024
|
ATHA Energy advances exploration at Gemini and Angilak uranium projects
- ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has provided investors with an update on its 2024 exploration programs at its uranium projects. At its Gemini project in the Athabasca Basin, Saskatchewan, the company in late August kicked off a Phase 3 diamond drill program to expand the footprint of mineralization, targeting the down-dip extents of the Gemini Mineralized Zone (GMZ).
- 08/28/2024
|
Are Medical Stocks Lagging Athira Pharma (ATHA) This Year?
- Here is how Athira Pharma, Inc. (ATHA) and HCA Healthcare (HCA) have performed compared to their sector so far this year.
- 08/23/2024
|
ATHA Energy signs LOI for joint venture on Canadian uranium projects
- ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) announced on Tuesday that it has signed a non-binding letter of intent (LOI) with Australian-listed Terra Uranium Ltd (ASX:T92) for a potential joint venture on key uranium exploration projects in Saskatchewan's Athabasca Basin. The proposed deal involves an option for Terra Uranium to acquire a 70% interest in ATHA's Spire and Horizon properties, while ATHA could gain up to a 60% stake in Terra Uranium's Pasfield Lake property.
- 08/20/2024
|
ATHA Energy Announces Proposed Option Agreements with Terra Uranium for Spire, Horizon, and Pasfield Projects
- VANCOUVER, British Columbia, Aug. 20, 2024 (GLOBE NEWSWIRE) -- ATHA Energy Corp. (TSXV: SASK) (FRA: X5U) (OTCQB: SASKF) (“ATHA”) is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”) with Terra Uranium Ltd. (ASX: T92) (“T92”), whereby the parties will work to negotiate a definitive option and joint venture agreement for T92 to earn an option to acquire a 70% interest in ATHA's Spire and Horizon properties (together, the “Spire Horizon Projects”) and a definitive option and joint venture agreement for ATHA to earn an option to acquire up to a 60% interest in T92's Pasfield Lake property (the “Pasfield Project”).
- 08/20/2024
|
Is Athira Pharma (ATHA) Stock Outpacing Its Medical Peers This Year?
- Here is how Athira Pharma, Inc. (ATHA) and HCA Healthcare (HCA) have performed compared to their sector so far this year.
- 08/07/2024
|
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
- Topline data from completed Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease targeted for September 2024 Phase 2/3 LIFT-AD data to be presented in an oral presentation at CTAD in October 2024 Phase 1 clinical trial of ATH-1105 underway for the potential treatment of amyotrophic lateral sclerosis (ALS) BOTHELL, Wash., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended June 30, 2024, and provided recent pipeline and business updates.
- 08/01/2024
|
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024
- Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms that may contribute to pTau pathology
- 07/31/2024
|
Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up
- Athira (ATHA) completes dosing the last patient in the phase II/III LIFT-AD study on fosgonimeton for treating people with mild-to-moderate Alzheimer's disease. Stock gains.
- 07/10/2024
|
ATHA Energy expands uranium footprint at Angilak
- ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) said its 2024 exploration program at the Angilak project has successfully expanded the uranium mineralization footprint with a 100% hit rate. The company updated on the progress of its 2024 exploration program at the Nunavut project, with the first six drill holes successfully expanding the footprint of uranium mineralization outside the historic Lac 50 Uranium Deposit.
- 07/10/2024
|
ATHA Energy Angilak 2024 Exploration Update: First Six Holes Successfully Expand Footprint of Uranium Mineralization With 100% Hit Rate Outside of Historic Resource
- HIGHLIGHTS: Angilak Project: The Angilak Project is host to the Lac 50 Uranium Deposit, which is one of the largest high-grade deposits outside of the Athabasca Basin, with a historical mineral resource estimate of 43.3M lbs at an average grade of 0.69% U3O8.1 In 2023, drilling at Angilak by Latitude Uranium (acquired by ATHA) intersected grades of up to 7.54 % U3O8 over 1.6 m. The 2024 Angilak Exploration Program is part of the Company's overall 2024 Exploration Program and consists of Phase I (diamond drilling) and Phase II (geophysics & ground geochemistry).
- 07/10/2024
|
ATHA Energy director's machine learning innovation recognized by Future Explorer's Competition
- ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) announced that its Director Geodata Drew Heasman, who leads its Digital Discovery team, has been awarded the top prize at the 2023/2024 Future Explorer's Competition. Organized by Humyn AI and funded by Dundee Precious Metals, the Future Explorer's Competition began in November 2023 and brings together more than 200 data scientists and geoscientists from 37 countries.
- 06/17/2024
|
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients
- Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients
- 06/12/2024
|
Glancy Prongay & Murray LLP and Labaton Keller Sucharow LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Athira Pharma, Inc. - (NASDAQ: ATHA)
- SEATTLE , June 10, 2024 /PRNewswire/ -- Nacif, et al. v. Athira Pharma, Inc., et al.
- 06/10/2024
|
ATHA Energy commences 2024 Angilak diamond drilling program
- ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has commenced Phase I of its 2024 Angilak Diamond Drilling Exploration Program at its Angilak Project in Nunavut. The program involves around 10,000 meters of diamond drilling, targeting the expansion of high-grade uranium mineralization at the Lac 50 Deposit and adjacent zones.
- 06/03/2024
|
Athira Pharma to Participate in Upcoming June Conferences
- Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer's Disease on Track for Second Half of 2024 Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer's Disease on Track for Second Half of 2024
- 05/29/2024
|
ATHA Energy enters option agreement with Riverboat Energy for Vista property in Athabasca Basin
- ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has signed an option agreement with Riverboat Energy Corporation, granting Riverboat the exclusive option to acquire a 70% interest in ATHA's Vista property in the Athabasca Basin. The agreement, effective May 20, 2024, allows Riverboat to earn the interest by fulfilling specified cash payments, share issuances, and exploration expenditures on the Vista property.
- 05/28/2024
|
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
- BOTHELL, Wash., May 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that the U.S. District Court for the Western District of Washington issued an order providing for preliminary approval of a proposed settlement of the claims asserted nominally on behalf of Athira against the individual defendants named in the previously disclosed stockholder derivative actions entitled Bushansky v. Kawas et al., No. 2:22-cv-497 and Houlihan v. Kawas et al., No. 2:22-cv-620, pending before the court. The proposed settlement calls for Athira to adopt certain corporate governance reforms and pay lead plaintiffs' attorney's fees, litigation expenses, and lead plaintiff service awards.
- 05/17/2024
|
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
- Topline data from Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease expected in second half of 2024 Submitted Investigational New Drug application to U.S. Food and Drug Administration for ATH-1105 for the treatment of amyotrophic lateral sclerosis; On track to dose subjects in a first-in-human study in second quarter of 2024 Strong balance sheet to support innovative pipeline through key clinical inflection points BOTHELL, Wash., May 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended March 31, 2024, and provided recent pipeline and business updates.
- 05/15/2024
|
Athira Pharma to Participate in Upcoming May Conferences
- BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in May.
- 05/02/2024
|
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
- BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D.
- 04/15/2024
|
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease
- BOTHELL, Wash., April 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the publication of preclinical data supporting the therapeutic potential of fosgonimeton in Alzheimer's disease.
- 04/11/2024
|
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
- Presentation to highlight therapeutic potential of Athira's small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis Presentation to highlight therapeutic potential of Athira's small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis
- 04/03/2024
|
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International Conference
- Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's & Parkinson's Diseases at AD/PD™ 2024
- 03/08/2024
|
Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy?
- Does Athira Pharma, Inc. (ATHA) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 02/28/2024
|
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
- Enrollment completed in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease; topline data expected in second half of 2024 On track to initiate first-in-human studies of ATH-1105 for the treatment of amyotrophic lateral sclerosis in first half of 2024 Strong balance sheet to support innovative pipeline through key inflection points BOTHELL, Wash., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2023, and reviewed recent pipeline and business updates.
- 02/22/2024
|
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
- Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
- 02/08/2024
|
ATHA Energy unveils promising results from North Valour-East Project electromagnetic surveys amidst strategic uranium expansion
- ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has announced results from its large-scale electromagnetic (EM) surveys at the 100%-owned North Valour-East Project in Saskatchewan's Athabasca Basin. The project, located within the North Rim Exploration District, has revealed numerous conductors with interpreted cross-cutting structures related to the Black Bay Fault, known for hosting historic uranium mines.
- 01/17/2024
|
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
- Completed enrollment in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease and expects topline data in second half of 2024 Plans to initiate first-in-human studies of ATH-1105 to treat amyotrophic lateral sclerosis in first half of 2024 BOTHELL, Wash., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today provided a clinical pipeline outlook and business update for 2024.
- 01/08/2024
|
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease
- Topline data from LIFT-AD on track for second half of 2024 Previously reported independent, unblinded interim analysis supports trial continuation and potential clinically meaningful activity of fosgonimeton Potential first-in-class approach focused on HGF modulation for treatment of neurodegenerative diseases BOTHELL, Wash., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced completion of enrollment in the Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease.
- 01/03/2024
|
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
- Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative diseases
- 12/12/2023
|
These biotechs targeting multiple neurodegenerative diseases
- Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive functions, motor functions, or sometimes both.
- 12/01/2023
|
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
- Company Presentation to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development in neurodegenerative diseases, including Alzheimer's disease Company Presentation to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development in neurodegenerative diseases, including Alzheimer's disease
- 11/29/2023
|
Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease
- BOTHELL, Wash., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented new preclinical data supporting the potential therapeutic benefit of fosgonimeton for the treatment of Alzheimer's disease (AD) and other neurodegenerative diseases at the Society for Neuroscience (SfN) Annual Meeting 2023, being held in Washington, D.C.
- 11/15/2023
|
Athira Pharma to Participate in Jefferies London Healthcare Conference
- BOTHELL, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate at the Jefferies London Healthcare Conference, taking place from November 14-16, 2023, in London. Details are as follows:
- 11/08/2023
|
Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
- New results support the neuroprotective effects of ATH-1105 in preclinical models of ALS, as indicated by consistent reduction in plasma neurofilament light chain (NfL) levels and preservation of motor function Data presented at invitational Northeast ALS Consortium (NEALS) meeting BOTHELL, Wash., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented new preclinical data supporting the potential benefit of ATH-1105 for the treatment of amyotrophic lateral sclerosis (ALS) at the 22 nd Annual Northeast ALS Consortium (NEALS) Meeting, taking place October 4-6, 2023, virtually and in-person in Clearwater, Florida.
- 10/05/2023
|
Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
- BOTHELL, Wash., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference taking place from September 26-28, 2023 in New York City. Details are as follows:
- 09/19/2023
|
All You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to Buy
- Athira Pharma, Inc. (ATHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 09/08/2023
|
Down -24.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Athira Pharma, Inc. (ATHA)
- Athira Pharma, Inc. (ATHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 08/31/2023
|
Athira Pharma to Participate in Upcoming May Investor Conferences
- BOTHELL, Wash., May 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will participate in the following upcoming investor conferences:
- 05/08/2023
|
Athira Pharma, Inc. (ATHA) Upgraded to Buy: What Does It Mean for the Stock?
- Athira Pharma, Inc. (ATHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 03/28/2023
|
Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences
- BOTHELL, Wash., March 06, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will participate in two upcoming scientific conferences: American Society for Experimental Neurotherapeutics (ASENT) 2023 Annual Meeting, which will be held virtually from Mar. 13-15, 2023, and AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD), which will be held in Gothenburg, Sweden and virtually from Mar. 28-Apr. 1, 2023.
- 03/06/2023
|
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
- HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALS HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALS
- 11/28/2022
|
Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer's Disease (CTAD) Conference
- Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration
- 11/21/2022
|
Athira Pharma to Present at Stifel 2022 Healthcare Conference
- BOTHELL, Wash., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that members of Athira's management team will participate in the Stifel 2022 Healthcare Conference taking place Nov. 15-16, 2022 in New York City. Members of management will participate in a fireside chat on Wednesday, Nov. 16, 2022 at 4:45 p.m. EST.
- 11/09/2022
|
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference
- Data supports neuroprotective and disease modifying potential in models of Parkinson's disease and diabetic neuropathy Data supports neuroprotective and disease modifying potential in models of Parkinson's disease and diabetic neuropathy
- 11/07/2022
|
Trading Ideas On The Upcoming CTAD 2022 Conference
- The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.
- 11/02/2022
|
Athira Pharma: Fosgonimeton May Outperform Lecanemab In Alzheimer's
- Athira Pharma's stock has sold off some months ago on its Alzheimer's drug candidate Fosgonimeton not meeting a primary endpoint in a randomized Phase 2 trial. The monotherapy arm did show remarkable efficacy, which appears stronger than 27% slowing of cognitive decline.
- 10/20/2022
|
Athira Pharma to Present Clinical and Preclinical Data at Alzheimer's Association International Conference 2022
- BOTHELL, Wash., July 25, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the details of its participation at the Alzheimer's Association International Conference (AAIC) 2022 being held in San Diego, Calif. and virtually from July 31 – August 4, 2022.
- 07/25/2022
|
Athira Pharma stock loses two-thirds of its value after study of Alzheimer's treatment misses primary endpoint
- Shares of Athira Pharma Inc. apha plummeted 66.9% toward a record low in active afternoon trading Wednesday, enough to make them the biggest decliners trading on major market indexes, after the biopharmaceutical company said a Phase 2 study of its Alzheimer's treatment failed to meet the primary endpoint. Trading volume spiked up to 18.1 million shares, compared with the full-day average over the past 30 days of about 246,500 shares.
- 06/22/2022
|
Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug
- Athira Pharma has just read out first Phase 2 results in one of two Alzheimer's trials. Its drug candidate ATH-1017 targets the HGF/MET pathway, a unique approach which has led to promising Phase 1 data.
- 06/22/2022
|
Why Athira Pharma Stock Imploded Today
- Its mid-stage clinical trial failed to help patients with Alzheimer's.
- 06/22/2022
|
Athira Pharma (ATHA) Stock Plunges 65% on Disappointing Drug Trial Results
- Athira Pharma (ATHA) stock is plummeting on Wednesday following the outcome of a Phase 2 clinical trial of fosgonimeton. The post Athira Pharma (ATHA) Stock Plunges 65% on Disappointing Drug Trial Results appeared first on InvestorPlace.
- 06/22/2022
|
Athira Pharma Shares Fall To 52-Week Low - Read Why
- Athira Pharma Inc (NASDAQ: ATHA) shares are falling to 52-week lows after announcing disappointing topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton (ATH-1017) in mild-to-moderate Alzheimer's disease (AD). The study did not meet the primary endpoint.
- 06/22/2022
|
Why Athira Pharma Stock Is Plunging
- Athira Pharma Inc (NASDAQ: ATHA) shares are falling Wednesday after the company announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer's disease. Athira said the primary endpoint of change in biomarker.
- 06/22/2022
|
Is Athira Pharma, Inc. (ATHA) Outperforming Other Medical Stocks This Year?
- Here is how Athira Pharma, Inc. (ATHA) and HCA Healthcare (HCA) have performed compared to their sector so far this year.
- 03/30/2022
|
Athira Pharma, Inc. (ATHA) CEO Mark Litton on Q4 2021 Results - Earnings Call Transcript
- Athira Pharma, Inc. (ATHA) CEO Mark Litton on Q4 2021 Results - Earnings Call Transcript
- 03/24/2022
|
Athira Pharma to Participate in Two Upcoming Investor Conferences
- BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that members of Athira Pharma's senior management team will participate in the following upcoming investor conferences.
- 03/21/2022
|
Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in Mild-to-Moderate Alzheimer's Disease at AD/PD™ 2022 Congress
- BOTHELL, Wash., March 14, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that an overview and update of the fully enrolled ACT-AD Phase 2 clinical trial with Athira's lead development candidate fosgonimeton (ATH-1017) in mild-to-moderate Alzheimer's disease, will be presented at the International Conference on Alzheimer's & Parkinson Diseases™ 2022, AD/PD™ 2022 hybrid congress, taking place March 15-20, 2022 virtually and in Barcelona.
- 03/14/2022
|
Athira Pharma to Present Preclinical Data at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
- Oral presentation on neurotrophic and procognitive properties of the active metabolite of fosgonimeton in preclinical models
- 02/22/2022
|
Is the Options Market Predicting a Spike in Athira Pharma (ATHA) Stock?
- Investors need to pay close attention to Athira Pharma (ATHA) stock based on the movements in the options market lately.
- 12/13/2021
|
Athira Pharma to Present at Upcoming Investor Conferences
- -Stifel 2021 Virtual Healthcare Conference- - Jefferies 2021 London Healthcare Conference-
- 11/08/2021
|
Why Shares of Athira Pharma Are Climbing Today
- The clinical trial for its Alzheimer's drug is one step closer to completion.
- 10/22/2021
|
Ex-Athira Pharma CEO Leen Kawas resigns and leaves board after image manipulation investigation
- Leen Kawas has formally resigned as CEO of Athira Pharma and is stepping off the board after an investigation found the biotech executive altered images in scientific papers she authored.
- 10/21/2021
|
Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017 at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Conference
- BOTHELL, Wash., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that updates and baseline data from two ongoing Phase 2 and Phase 2/3 clinical trials of its lead development candidate ATH-1017, a novel small molecule therapeutic specifically designed to enhance the activity of Hepatocyte Growth Factor (HGF) and its receptor MET, in mild-to-moderate Alzheimer's disease, will be presented as an oral presentation at the upcoming 2021 Clinical Trials on Alzheimer's Disease (CTAD) conference taking place Nov. 9-12, 2021 both virtually and in-person in Boston.
- 09/29/2021
|
Athira Pharma, Inc. (ATHA) Dips More Than Broader Markets: What You Should Know
- Athira Pharma, Inc. (ATHA) closed at $10.13 in the latest trading session, marking a -1.65% move from the prior day.
- 09/17/2021
|
Athira Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - August 27, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) and reminds investors of the August 24, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $100,000 investing in Athira stock purchased pursuant...
- 08/27/2021
|
Last Day for Shareholders to Actively Participate in Athira Pharma, Inc. (ATHA) Class Action: Bronstein, Gewirtz & Grossman, LLC
- NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Athira Pharma, Inc. ("Athira " or "the Company") (NASDAQ: ATHA) on behalf of shareholders who purchased or otherwise acquired Athira common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's September 2020 initial public offering
- 08/24/2021
|
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - August 24, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 08/24/2021
|
ATHA DEADLINE TODAY: Hagens Berman Encourages Athira Pharma (ATHA) Investors with Losses to Contact Firm's Attorneys Now, Lead Plaintiff Deadline Today
- San Francisco, California--(Newsfile Corp. - August 24, 2021) - Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims. Class Period: Sept. 18, 2020 - June 17, 2021Lead Plaintiff Deadline: Aug. 24, 2021Visit: www.hbsslaw.com/investor-fraud/ATHAContact An Attorney Now: ATHA@hbsslaw.com 844-916-0895Athira Pharma, Inc. (ATHA) Securities Class Action:Since going public...
- 08/24/2021
|
Kessler Topaz Meltzer & Checker, LLP: Final Deadline Reminder for Athira Pharma, Inc. Investors – ATHA
- RANDOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that securities fraud class action lawsuits have been filed against Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira”) on behalf of those who purchased or acquired Athira common stock: a) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Athira's September 2020 initial public offering (“IPO”); and/or b) betw
- 08/23/2021
|
DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - August 23, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 08/23/2021
|
Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer's Disease Summit
- BOTHELL, Wash., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Chief Medical Officer, Hans Moebius, will present on the application of clinically established Evoked-Response Potentials (ERPs) by using ERP P300 in Alzheimer's drug development, and the utility of ERP P300 in Athira's Phase 1 clinical trials, at the Annual Biomarkers for Alzheimer's Disease Summit taking place virtually August 24-26, 2021.
- 08/23/2021
|
FINAL DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Athira Pharma, Inc. Investors to Secure Counsel Before Important August 24 Deadline in Securities Class Action - ATHA
- New York, New York--(Newsfile Corp. - August 23, 2021) - WHY: New York, N.Y., August 22, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athira Pharma, Inc. (NASDAQ: ATHA): (a) pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO" or "Offering"); and/or (b) between September 18, 2020 and June 17, 2021, both dates inclusive (the "Class Period"), of the important August...
- 08/23/2021
|
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athira Pharma, Inc. (ATHA)
- LOS ANGELES--(BUSINESS WIRE)---- $ATHA #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athira Pharma, Inc. (ATHA)
- 08/23/2021
|
Athira Class Action Reminder
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - August 22, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) and reminds investors of the August 24, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Athira stock purchased pursuant...
- 08/22/2021
|
FINAL NOTICE: Investors with Substantial Losses Have Opportunity to Lead the Athira Pharma, Inc. Class Action Lawsuit - ATHA
- SAN DIEGO, Aug. 21, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Athira Pharma, Inc. (NASDAQ: ATHA) securities between September 18, 2020 and June 17, 2021, inclusive (the "Class Period"), have until August 24, 2021 to seek appointment as lead plaintiff in the Athira Pharma class action lawsuit. The Athira Pharma class action lawsuit (Wang v.
- 08/21/2021
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Athira Pharma, Inc. (ATHA) Investors
- LOS ANGELES, Aug. 20, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's September 2020 initial public offering ("IPO" or the "Offering").
- 08/20/2021
|
TUESDAY DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - August 20, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 08/20/2021
|
ATHIRA PHARMA SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Athira Pharma, Inc. - ATHA
- New Orleans, Louisiana--(Newsfile Corp. - August 19, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 24, 2021 to file lead plaintiff applications in securities class action lawsuits against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA), if they purchased the Company's securities between September 18, 2020 through June 17, 2021, inclusive (the "Class Period") and/or...
- 08/19/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athira Pharma, Inc. - ATHA
- NEW YORK, Aug. 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of. Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA).
- 08/19/2021
|
Athira Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - August 19, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) and reminds investors of the August 24, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Athira stock purchased pursuant...
- 08/19/2021
|
TUESDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - August 19, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 08/19/2021
|
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athira Pharma, Inc. (ATHA)
- BENSALEM, Pa. – , Aug. 18, 2021 /PRNewswire/ -- Law Offices of Howard G.
- 08/18/2021
|
TUESDAY DEADLINE: Investors with Substantial Losses Have Opportunity to Lead the Athira Pharma, Inc. Class Action Lawsuit – ATHA
- SAN DIEGO--(BUSINESS WIRE)-- #ATHAstock--The suit alleges defendants issued false statements concerning Athira business and prospects, resulting in its stock trading at inflated prices.
- 08/18/2021
|
Final Deadline Approaching on August 24, 2021: Kessler Topaz Meltzer & Check, LLP Reminds Athira Pharma, Inc. Investors of Class Action Lawsuit Deadline
- Radnor, Pennsylvania--(Newsfile Corp. - August 17, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds Athira Pharma, Inc. (NASDAQ: ATHA) ("Athira") investors that securities fraud class action lawsuits have been filed on behalf of those who purchased or acquired Athira common stock: a) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Athira's September 2020 initial public offering ("IPO"); and/or b) between...
- 08/17/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $ATHA #ATHA--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc.
- 08/17/2021
|
Athira Pharma extends Alzheimer's clinical trial, adds new execs after CEO placed on leave
- Athira Pharma is advancing its clinical trials in the wake of allegations of image manipulation in papers authored by its CEO, the company reported today in its second quarter financial and business update.
- 08/16/2021
|
Athira Pharma Reports Second Quarter 2021 Financial Results and Business Update
- - Initiated open label extension for LIFT-AD and ACT-AD trials of ATH-1017 allowing for an additional six months of treatment
- 08/16/2021
|
Wolf Popper LLP Reminds Athira Pharma, Inc. (ATHA) Investors of August 24, 2021 Lead Plaintiff Filing Deadline
- New York, New York--(Newsfile Corp. - August 16, 2021) - Wolf Popper LLP reminds Athira Pharma, Inc. (NASDAQ: ATHA) investors that federal securities class action lawsuits have been filed in the U.S. District Court for the Western District of Washington against Athira Pharma and certain of its officers, directors, and IPO underwriters. The deadline for Athira investors to seek appointment as the lead plaintiff in the lawsuits is August 24, 2021.The securities class actions...
- 08/16/2021
|
Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Athira Pharma, Inc.
- Radnor, Pennsylvania--(Newsfile Corp. - August 15, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds Athira Pharma, Inc. (NASDAQ: ATHA) ("Athira") investors that securities fraud class action lawsuits have been filed on behalf of those who purchased or acquired Athira common stock: a) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Athira's September 2020 initial public offering ("IPO"); and/or b)...
- 08/15/2021
|
Investor Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Athira Pharma, Inc. - ATHA
- Radnor, Pennsylvania--(Newsfile Corp. - August 14, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that securities fraud class action lawsuits have been filed against Athira Pharma, Inc. (NASDAQ: ATHA) ("Athira") on behalf of those who purchased or acquired Athira common stock: a) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Athira's September 2020 initial public offering; and/or b)...
- 08/14/2021
|
ROSEN, A TOP RANKED LAW FIRM, Encourages Athira Pharma, Inc. Investors to Secure Counsel Before Important August 24 Deadline in Securities Class Action - ATHA
- NEW YORK, Aug. 13, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athira Pharma, Inc. (NASDAQ: ATHA): (a) pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO" or "Offering"); and/or (b) between September 18, 2020 and June 17, 2021, both dates inclusive (the "Class Period"), of the important August 24, 2021 lead plaintiff deadline. SO WHAT: If you purchased Athira securities pursuant and/or traceable to the Company's IPO and/or during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 08/13/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Athira Pharma (ATHA) Investors of AUGUST 24th INVESTOR DEADLINE in Securities Class Action, Encourages Investors with Losses to Contact Firm's Attorneys Now
- San Francisco, California--(Newsfile Corp. - August 13, 2021) - Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims. Class Period: Sept. 18, 2020 - June 17, 2021Lead Plaintiff Deadline: Aug. 24, 2021Visit: www.hbsslaw.com/investor-fraud/ATHAContact An Attorney Now: ATHA@hbsslaw.com 844-916-0895Athira Pharma, Inc. (ATHA) Securities Class Action:Since going public...
- 08/13/2021
|
Lawsuits Filed Against ATHA, YMM and PLL - Jakubowitz Law Pursues Shareholders Claims
- NEW YORK, NY / ACCESSWIRE / August 12, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court.
- 08/12/2021
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - August 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 08/12/2021
|
ROSEN, LEADING INVESTOR COUNSEL, Encourages Athira Pharma, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATHA
- New York, New York--(Newsfile Corp. - August 11, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athira Pharma, Inc. (NASDAQ: ATHA): (a) pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO" or "Offering"); and/or (b) between September 18, 2020 and June 17, 2021, both dates inclusive (the "Class Period"), of the important August 24, 2021 lead plaintiff deadline.SO...
- 08/11/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Athira Pharma (ATHA) Investors to AUGUST 24th APPLICATION DEADLINE in Securities Class Action, Encourages Investors with Losses to Contact Firm's Attorneys Now
- San Francisco, California--(Newsfile Corp. - August 11, 2021) - Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims. Class Period: Sept. 18, 2020 - June 17, 2021Lead Plaintiff Deadline: Aug. 24, 2021Visit: www.hbsslaw.com/investor-fraud/ATHAContact An Attorney Now: ATHA@hbsslaw.com 844-916-0895Athira Pharma, Inc. (ATHA) Securities Class Action:Since going public...
- 08/11/2021
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - August 11, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 08/11/2021
|
SHAREHOLDER ALERT: ATHA RKT ATVI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
- NEW YORK, NY / ACCESSWIRE / August 11, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
- 08/11/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - August 10, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 08/10/2021
|
Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Athira Pharma, Inc.
- Radnor, Pennsylvania--(Newsfile Corp. - August 7, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of Athira Pharma, Inc. (NASDAQ: ATHA) ("Athira") that securities fraud class action lawsuits have been filed on behalf of those who purchased or acquired Athira common stock: a) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Athira's September 2020 initial public offering ("IPO"); and/or b)...
- 08/07/2021
|
Athira Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - August 6, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) and reminds investors of the August 24, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Athira stock purchased pursuant...
- 08/06/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Athira Pharma (ATHA) Investors of Lead Plaintiff Opportunity in Securities Class Action, Encourages Investors with Losses to Contact the Firm Now
- San Francisco, California--(Newsfile Corp. - August 6, 2021) - Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims. Class Period: Sept. 18, 2020 - June 17, 2021Lead Plaintiff Deadline: Aug. 24, 2021Visit: www.hbsslaw.com/investor-fraud/ATHAContact An Attorney Now: ATHA@hbsslaw.com 844-916-0895Athira Pharma, Inc. (ATHA) Securities Class Action:Since going public...
- 08/06/2021
|
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - August 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 08/06/2021
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ATHA, BZ and ATVI
- NEW YORK, NY / ACCESSWIRE / August 6, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
- 08/06/2021
|
ATHIRA PHARMA SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 Of Lead Plaintiff Deadline in Class Action Lawsuits Against Athira Pharma, Inc. - ATHA
- New Orleans, Louisiana--(Newsfile Corp. - August 5, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 24, 2021 to file lead plaintiff applications in securities class action lawsuits against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA), if they purchased the Company's securities between September 18, 2020 through June 17, 2021, inclusive (the "Class Period") and/or...
- 08/05/2021
|
Athira Pharma Mourns the Loss of Chair of Board of Directors, Tadataka Yamada, M.D.
- BOTHELL, Wash., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, mourns the passing of Tadataka “Tachi” Yamada, M.D., the chair of the company's board of directors.
- 08/05/2021
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athira Pharma, Inc. (ATHA)
- LOS ANGELES, Aug. 5, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming August 24, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA): (a) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's September 2020 initial public offering ("IPO" or the "Offering"); and/or (b) securities between September 18, 2020 and June 17, 2021 , inclusive (the "Class Period"). If you suffered a loss on your Athira investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/athira-pharma-inc/.
- 08/05/2021
|
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - August 5, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 08/05/2021
|
Athira (ATHA) to Report Q2 Earnings: What's in the Cards?
- Investor focus to be on the company's pipeline progress, mainly on its small molecule candidate ATH-1017 for Alzheimer's disease, on Athira's (ATHA) second-quarter earnings call.
- 08/04/2021
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ATHA, DKNG and DIDI
- NEW YORK, NY / ACCESSWIRE / August 4, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.
- 08/04/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athira Pharma, Inc. - ATHA
- NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of . Athira Pharma, Inc. (" Athira " or the "Company") (NASDAQ: ATHA).
- 08/03/2021
|
CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Athira Pharma, Inc. Shareholders of Securities Fraud Class Action Lawsuit
- RADNOR, Pa., Aug. 3, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds Athira Pharma, Inc. (NASDAQ: ATHA) ("Athira") investors that securities fraud class action lawsuits have been filed on behalf of those who purchased or acquired Athira common stock: a) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Athira's September 2020 initial public offering ("IPO"); and/or b) between September 18, 2020 and June 17, 2021 , inclusive (the "Class Period").
- 08/03/2021
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ATHA, BLCT and OTLY
- NEW YORK, NY / ACCESSWIRE / August 3, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.
- 08/03/2021
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - August 3, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 08/03/2021
|
ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Athira Pharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ATHA
- NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athira Pharma, Inc. (NASDAQ: ATHA): (a) pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the “IPO” or “Offering”); and/or (b) between September 18, 2020 and June 17, 2021, both dates inclusive (the “Class Period”), of the important August 24, 2021 lead plaintiff deadline. SO WHAT: If you purchased Athira securities pursuant and
- 08/02/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - August 2, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 08/02/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athira Pharma, Inc. - ATHA
- New York, New York--(Newsfile Corp. - August 1, 2021) - Pomerantz LLP is investigating claims on behalf of investors of. Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Athira and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 08/01/2021
|
Rosen, Global Investor Counsel, Encourages Athira Pharma, Inc. Investors to Secure Counsel Before Important August 24 Deadline in Securities Class Action - ATHA
- New York, New York--(Newsfile Corp. - July 31, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athira Pharma, Inc. (NASDAQ: ATHA): (a) pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO" or "Offering"); and/or (b) between September 18, 2020 and June 17, 2021, both dates inclusive (the "Class Period"), of the important August 24, 2021 lead plaintiff deadline.SO...
- 07/31/2021
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SRAC, ATHA and COIN
- NEW YORK, NY / ACCESSWIRE / July 30, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.
- 07/30/2021
|
HAGENS BERMAN Reminds Athira Pharma (ATHA) Investors of Securities Class Action and Encourages Investors with Losses to Contact Firm's Attorneys
- San Francisco, California--(Newsfile Corp. - July 30, 2021) - Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims. Class Period: Sept. 18, 2020 - June 17, 2021Lead Plaintiff Deadline: Aug. 24, 2021Visit: www.hbsslaw.com/investor-fraud/ATHAContact An Attorney Now: ATHA@hbsslaw.com 844-916-0895Athira Pharma, Inc. (ATHA) Securities Class Action:Since going public...
- 07/30/2021
|
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 30, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 07/30/2021
|
ATHIRA PHARMA SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Athira Pharma, Inc. - ATHA
- New Orleans, Louisiana--(Newsfile Corp. - July 29, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 24, 2021 to file lead plaintiff applications in securities class action lawsuits against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA), if they purchased the Company's securities between September 18, 2020 through June 17, 2021, inclusive (the "Class Period") and/or...
- 07/29/2021
|
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 29, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 07/29/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athira Pharma, Inc. - ATHA
- NEW YORK, July 28, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of. Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA).
- 07/28/2021
|
ATHA ALERT: Robbins Geller Rudman & Dowd LLP Announces Opportunity for Investors with Substantial Losses to Lead the Athira Pharma, Inc. Class Action Lawsuit
- San Diego, California--(Newsfile Corp. - July 28, 2021) - Robbins Geller Rudman & Dowd LLP announces the filing of the Athira Pharma class action lawsuit, which charges Athira Pharma, Inc. (NASDAQ: ATHA) and its CEO and directors, as well as the underwriters of Athira Pharma's September 2020 initial public offering ("IPO"), with violations of the Securities Exchange Act of 1934 and/or Securities Act of 1933. The Athira Pharma class action lawsuit seeks to represent:...
- 07/28/2021
|
HAGENS BERMAN, NATIONAL ATTORNEYS, Alerts Athira Pharma (ATHA) Investors to Securities Class Action and Advises Investors with Losses to Contact Firm's Attorneys
- San Francisco, California--(Newsfile Corp. - July 28, 2021) - Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims. Class Period: Sept. 18, 2020 - June 17, 2021Lead Plaintiff Deadline: Aug. 24, 2021Visit: www.hbsslaw.com/investor-fraud/ATHAContact An Attorney Now: ATHA@hbsslaw.com 844-916-0895Athira Pharma, Inc. (ATHA) Securities Class Action:Since going public...
- 07/28/2021
|
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 28, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 07/28/2021
|
Athira Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - July 27, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) and reminds investors of the August 24, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Athira stock purchased pursuant...
- 07/27/2021
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 27, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 07/27/2021
|
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Athira Pharma, Inc. Investors to Secure Counsel Before Important August 24 Deadline in Securities Class Action - ATHA
- NEW YORK, July 26, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athira Pharma, Inc. (NASDAQ: ATHA): (a) pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO" or "Offering"); and/or (b) between September 18, 2020 and June 17, 2021, both dates inclusive (the "Class Period"), of the important August 24, 2021 lead plaintiff deadline. SO WHAT: If you purchased Athira securities pursuant and/or traceable to the Company's IPO and/or during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 07/26/2021
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 26, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 07/26/2021
|
Class Action Lawsuit Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Athira Pharma, Inc.
- Radnor, Pennsylvania--(Newsfile Corp. - July 25, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of Athira Pharma, Inc. (NASDAQ: ATHA) ("Athira") that securities fraud class action lawsuits have been filed on behalf of those who purchased or acquired Athira common stock: a) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Athira's September 2020 initial public offering ("IPO"); and/or b)...
- 07/25/2021
|
Athira Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - July 24, 2021) - NEW YORK -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) and reminds investors of the August 24, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.If you suffered losses exceeding $50,000 investing in Athira stock...
- 07/24/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athira Pharma, Inc. - ATHA
- New York, New York--(Newsfile Corp. - July 23, 2021) - Pomerantz LLP is investigating claims on behalf of investors of. Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Athira and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 07/23/2021
|
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athira Pharma, Inc. (ATHA)
- BENSALEM, Pa., July 23, 2021 /PRNewswire/ -- Law Offices of Howard G.
- 07/23/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 23, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 07/23/2021
|
ATHIRA PHARMA SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Athira Pharma, Inc. - ATHA
- New Orleans, Louisiana--(Newsfile Corp. - July 22, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 24, 2021 to file lead plaintiff applications in securities class action lawsuits against Athira Pharma, Inc. ("Athira" or the "Company") (NasdaqGS: ATHA), if they purchased the Company's securities between September 18, 2020 through June 17, 2021, inclusive (the "Class Period") and/or...
- 07/22/2021
|
Athira Update
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - July 22, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) and reminds investors of the August 24, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Athira stock purchased pursuant...
- 07/22/2021
|
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 22, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 07/22/2021
|
Athira Class Action Reminder
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - July 21, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) and reminds investors of the August 24, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Athira stock purchased pursuant...
- 07/21/2021
|
Class Action Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Athira Pharma, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit
- RADNOR, Pa., July 20, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of Athira Pharma, Inc. (NASDAQ: ATHA) ("Athira") that securities fraud class action lawsuits have been filed on behalf of those who purchased or acquired Athira common stock: a) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Athira's September 2020 initial public offering ("IPO"); and/or b) between September 18, 2020 and June 17, 2021 , inclusive (the "Class Period").
- 07/20/2021
|
ATHA DEADLINE: Investors With Substantial Losses Have Opportunity to Lead the Athira Pharma, Inc. Class Action Lawsuit
- SAN DIEGO--(BUSINESS WIRE)-- #ATHAstock--The suit alleges defendants issued false statements concerning Athira business and prospects, resulting in its stock trading at inflated prices.
- 07/20/2021
|
Rosen, Leading and Longstanding Investor Counsel, Encourages Athira Pharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATHA
- New York, New York--(Newsfile Corp. - July 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athira Pharma, Inc. (NASDAQ: ATHA): (a) pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO" or "Offering"); and/or (b) between September 18, 2020 and June 17, 2021, both dates inclusive (the "Class Period"), of the important August 24, 2021 lead plaintiff deadline.SO...
- 07/20/2021
|
HAGENS BERMAN Encourages Athira Pharma (ATHA) Investors with Losses to Contact the Firm Now to Recover Losses Due to Alleged Securities Fraud
- San Francisco, California--(Newsfile Corp. - July 20, 2021) - Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims. Class Period: Sept. 18, 2020 - June 17, 2021Lead Plaintiff Deadline: Aug. 24, 2021Visit: www.hbsslaw.com/investor-fraud/ATHAContact An Attorney Now: ATHA@hbsslaw.com 844-916-0895Athira Pharma, Inc. (ATHA) Securities Class Action:Since going public...
- 07/20/2021
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 20, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 07/20/2021
|
ATHIRA INVESTORS: August 24, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser
- SAN FRANCISCO--(BUSINESS WIRE)---- $ATHA #ATHA--ATHIRA INVESTORS: August 24, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser
- 07/20/2021
|
Athira Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - July 19, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) and reminds investors of the August 24, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Athira stock purchased pursuant...
- 07/19/2021
|
LAWSUIT FILED: Block & Leviton LLP Has Filed a Lawsuit Against Athira Pharma, Inc. for Securities Fraud
- Boston, Massachusetts--(Newsfile Corp. - July 19, 2021) - Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, announces that it has filed a class action lawsuit on behalf of shareholders against Athira Pharma, Inc. (NASDAQ: ATHA) and certain of its executives for securities fraud. Investors who purchased Athira shares between September 18, 2020 and June 17, 2021 and who lost money are strongly encouraged to contact Block & Leviton attorneys at (617) 398-5600, via...
- 07/19/2021
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 19, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 07/19/2021
|
Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer's Association International Conference 2021 (AAIC)
- BOTHELL, Wash., July 19, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that it will present clinical electroencephalogram (EEG) data, including in Alzheimer's patients, from the Phase 1 a/b trial of its lead development candidate, ATH-1017, at the upcoming Alzheimer's Association International Conference 2021 (AAIC). AAIC will be held July 26-30, 2021, virtually and in Denver.
- 07/19/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athira Pharma, Inc. - ATHA
- NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of. Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA).
- 07/18/2021
|
Athira Update
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - July 17, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) and reminds investors of the August 24, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Athira stock purchased pursuant...
- 07/17/2021
|
ATHIRA SHAREHOLDERS: August 24, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser
- SAN FRANCISCO--(BUSINESS WIRE)---- $ATHA #ATHA--ATHIRA SHAREHOLDERS: August 24, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser
- 07/17/2021
|
Athira Class Action Reminder
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - July 16, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) and reminds investors of the August 24, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Athira stock purchased pursuant...
- 07/16/2021
|
INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That Class Action Lawsuits Have Been Filed Against Athira Pharma, Inc. and Encourages Investors to Contact the Firm Before August 24, 2021
- NEW YORK--(BUSINESS WIRE)---- $ATHA--The law firm of Kirby McInerney LLP reminds investors that securities fraud class action lawsuits have been filed in the United States District Court for the Western District of Washington against Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira” or the “Company”) on behalf of those who purchased or acquired Athira common stock: (a) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with
- 07/16/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 16, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 07/16/2021
|
ATHIRA PHARMA SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Athira Pharma, Inc. - ATHA
- New Orleans, Louisiana--(Newsfile Corp. - July 15, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 24, 2021 to file lead plaintiff applications in securities class action lawsuits against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA), if they purchased the Company's securities between September 18, 2020 through June 17, 2021, inclusive (the "Class Period") and/or...
- 07/15/2021
|
ATHA SHAREHOLDER ALERT: Shareholders With Substantial Losses Have Opportunity to Lead the Athira Pharma, Inc. Class Action Lawsuit
- San Diego, California--(Newsfile Corp. - July 15, 2021) - The Athira Pharma class action lawsuit charges Athira Pharma, Inc. (NASDAQ: ATHA) and its CEO with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers of Athira Pharma securities between September 18, 2020 and June 17, 2021, inclusive (the "Class Period"). The Athira Pharma class action lawsuit was commented in the Western District of Washington and is captioned Wang v....
- 07/15/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Athira Pharma (ATHA) Investors to Securities Fraud Lawsuit, Encourages Investors with Losses to Contact Firm's Attorneys Now
- San Francisco, California--(Newsfile Corp. - July 15, 2021) - Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims. Class Period: Sept. 18, 2020 - June 17, 2021Lead Plaintiff Deadline: Aug. 24, 2021Visit: www.hbsslaw.com/investor-fraud/ATHAContact An Attorney Now: ATHA@hbsslaw.com 844-916-0895Athira Pharma, Inc. (ATHA) Securities Class Action:Since going...
- 07/15/2021
|
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 15, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 07/15/2021
|
Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Athira Pharma, Inc. - ATHA
- Radnor, Pennsylvania--(Newsfile Corp. - July 14, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds Athira Pharma, Inc. (NASDAQ: ATHA) ("Athira") investors that securities fraud class action lawsuits have been filed on behalf of those who purchased or acquired Athira common stock: a) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Athira's September 2020 initial public offering ("IPO"); and/or b)...
- 07/14/2021
|
ATHA INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Athira Pharma, Inc. Class Action Lawsuit
- SAN DIEGO--(BUSINESS WIRE)-- #ATHAstock--The suit alleges defendants issued false statements concerning Athira business and prospects, resulting in its stock trading at inflated prices.
- 07/14/2021
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Athira Pharma, Inc. (ATHA) Investors
- LOS ANGELES, July 14, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's September 2020 initial public offering ("IPO" or the "Offering").
- 07/14/2021
|
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 14, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 07/14/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athira Pharma, Inc. - ATHA
- New York, New York--(Newsfile Corp. - July 13, 2021) - Pomerantz LLP is investigating claims on behalf of investors of. Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Athira and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 07/13/2021
|
Athira Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - July 13, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ:ATHA) and reminds investors of the August 24, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Athira stock purchased pursuant...
- 07/13/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Athira Pharma (ATHA) Investors to Contact Firm's Attorneys Now, Securities Class Action Filed
- San Francisco, California--(Newsfile Corp. - July 13, 2021) - Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims.Class Period: Sept. 18, 2020 - June 17, 2021Lead Plaintiff Deadline: Aug. 24, 2021Visit: www.hbsslaw.com/investor-fraud/ATHAContact An Attorney Now: ATHA@hbsslaw.com844-916-0895Athira Pharma, Inc. (ATHA) Securities Class Action:Since going public in September 2020, Athira
- 07/13/2021
|
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 13, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 07/13/2021
|
ATHA INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Athira Pharma, Inc.
- RADNOR, Pa., July 12, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that securities fraud class action lawsuits have been filed against Athira Pharma, Inc. (NASDAQ: ATHA) ("Athira") on behalf of those who purchased or acquired Athira common stock: a) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Athira's September 2020 initial public offering; and/or b) between September 18, 2020 and June 17, 2021 , inclusive (the "Class Period").
- 07/12/2021
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 07/12/2021
|
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Athira Pharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ATHA
- NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athira Pharma, Inc. (NASDAQ: ATHA): (a) pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the “IPO” or “Offering”); and/or (b) between September 18, 2020 and June 17, 2021, both dates inclusive (the “Class Period”), of the important August 24, 2021 lead plaintiff deadline. SO WHAT: If you purchased Athira securities pursuant and
- 07/10/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athira Pharma, Inc. - ATHA
- NEW YORK, July 10, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of. Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA).
- 07/10/2021
|
Athira Class Action Reminder
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - July 9, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) and reminds investors of the August 24, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Athira stock purchased pursuant...
- 07/09/2021
|
ROSEN, A LEADING LAW FIRM, Encourages Athira Pharma, Inc. Investors With Losses Over $100K to Secure Counsel Before Important August 24 Deadline in Securities Class Action - ATHA
- NEW YORK, July 9, 2021 /PRNewswire/ -- WHY: , Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athira Pharma, Inc. (NASDAQ: ATHA): (a) pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO" or "Offering"); and/or (b) between September 18, 2020 and June 17, 2021, both dates inclusive (the "Class Period"), of the important August 24, 2021 lead plaintiff deadline. SO WHAT: If you purchased Athira securities pursuant and/or traceable to the Company's IPO and/or during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 07/09/2021
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athira Pharma, Inc. (ATHA)
- LOS ANGELES, July 9, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming August 24, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA): (a) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's September 2020 initial public offering ("IPO" or the "Offering"); and/or (b) securities between September 18, 2020 and June 17, 2021 , inclusive (the "Class Period"). If you suffered a loss on your Athira investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/athira-pharma-inc/.
- 07/09/2021
|
SHAREHOLDER ALERT: Robbins LLP Announces that Athira Pharma, Inc. (ATHA) is Being Sued for Misleading Shareholders
- SAN DIEGO & BOTHELL, Wash.--(BUSINESS WIRE)---- $ATHA #ATHA--Shareholder rights law firm Robbins LLP announces that several class actions have been filed on behalf of all purchasers of Athira Pharma, Inc. (NASDAQ: ATHA) who acquired Athira securities between September 18, 2020 and June 17, 2021. The complaint asserts claims under the Securities Exchange Act of 1934. Athira is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration f
- 07/09/2021
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 9, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 07/09/2021
|
ATHIRA PHARMA SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Athira Pharma, Inc. - ATHA
- NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 24, 2021 to file lead plaintiff applications in securities class action lawsuits against Athira Pharma, Inc. (“Athira” or the “Company”) (NasdaqGS: ATHA), if they purchased the Company's securities between September 18, 2020 through June 17, 2021, inclusive (the “Class Period”) and/or pursuant to the Company's
- 07/08/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Advises Athira Pharma (ATHA) Investors to Contact Firm's Attorneys Now, Securities Fraud Lawsuit Filed
- San Francisco, California--(Newsfile Corp. - July 8, 2021) - Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims. Class Period: Sept. 18, 2020 - June 17, 2021Lead Plaintiff Deadline: Aug. 24, 2021Visit: www.hbsslaw.com/investor-fraud/ATHAContact An Attorney Now: ATHA@hbsslaw.com 844-916-0895Athira Pharma, Inc. (ATHA) Securities Class Action:Since going public...
- 07/08/2021
|
ATHA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Athira Pharma, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm
- New York, New York--(Newsfile Corp. - July 8, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Athira Pharma, Inc. ("Athira " or "the Company") (NASDAQ: ATHA) on behalf of shareholders who purchased or otherwise acquired Athira common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's September 2020 initial public offering ("IPO" or the...
- 07/08/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 8, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 07/08/2021
|
Athira Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - July 7, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) and reminds investors of the August 24, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Athira stock purchased pursuant...
- 07/07/2021
|
Athira Pharma Investor Alert: Goldman Scarlato & Penny Investor Rights Lawyers Evaluate Potential Individual, Non-Class Action Claims on Behalf of ATHA Investors
- PHILADELPHIA and CLEVELAND, July 7, 2021 /PRNewswire/ -- The investor rights attorneys at Goldman Scarlato & Penny, PC law firm ("GSP") are evaluating potential claims for compensation on behalf of investors who purchased Athira Pharma (Nasdaq: ATHA) shares either in its initial public offering ("IPO") or its private placements and suffered losses. The GSP attorneys plan to primarily seek compensation for Athira investors individually, rather than in a class action.
- 07/07/2021
|
Class Action Alert: Kessler Topaz Meltzer & Check, LLP Reminds ATHA Investors for Securities Fraud Class Action Lawsuit
- RADNOR, Pa., July 6, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that securities fraud class action lawsuits have been filed against Athira Pharma, Inc. (NASDAQ: ATHA) ("Athira") on behalf of those who purchased or acquired Athira common stock: a) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Athira's September 2020 initial public offering ("IPO"); and/or b) between September 18, 2020 and June 17, 2021 , inclusive (the "Class Period").
- 07/06/2021
|
ATHA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Athira Pharma, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm
- NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Athira Pharma, Inc. ("Athira " or "the Company") (NASDAQ: ATHA) on behalf of shareholders who purchased or otherwise acquired Athira common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's September 2020 initial public offering
- 07/06/2021
|
Athira Pharma Starts Open-Label Extension Of Alzheimer's Disease Trials
- Athira Pharma Inc (NASDAQ: ATHA) has started enrollment in an open-label extension (OLEX) study for its ongoing Phase 2/3 LIFT-AD and Phase 2 ACT-AD studies of ATH-1017 for the treatment of mild-to-moderate Alzheimer's disease. The LIFT-AD and ACT-AD trials evaluate ATH-1017, a small molecule therapeutic designed to enhance the activity of the Hepatocyte Growth Factor and its receptor, MET, which are expressed in the central nervous system, to promote brain health and function.
- 07/06/2021
|
Athira Pharma Announces Initiation of Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of ATH-1017 for Alzheimer's Disease
- Study Extension allows for additional 26 weeks of treatment on ATH-1017 Study Extension allows for additional 26 weeks of treatment on ATH-1017
- 07/06/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athira Pharma, Inc. - ATHA
- New York, New York--(Newsfile Corp. - July 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of. Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Athira and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 07/05/2021
|
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 5, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 07/05/2021
|
Biotech Losers In 2021 That Could Bounce Big In The Second Half
- Biotech stocks are tricky investment bets that require careful analysis and scrutiny. A stock that has fallen off a cliff in reaction to a binary event can neither be written off entirely nor picked as a bargain buy.
- 07/03/2021
|
Berger Montague Investigates Potential Securities Fraud Claims Against Athira Pharma, Inc. (ATHA); Lead Plaintiff Deadline is August 24, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - July 3, 2021) - Berger Montague is investigating potential securities fraud claims against Athira Pharma, Inc. ("Athira" or the "Company"). The Firm is investigating these allegations on behalf of investors who purchased Athira securities (NASDAQ: ATHA) between September 18, 2020 and June 17, 2021 (the "Class Period"), including shares purchased on or traceable to the Company's initial public offering in September 2020. If you purchased Athira securities during the Class Period...
- 07/03/2021
|
Athira Update
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - July 2, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ:ATHA) and reminds investors of the August 24, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Athira stock purchased pursuant and/or...
- 07/02/2021
|
Athira Pharma Stock: Berger Montague Investigates Securities Fraud Allegations Against Athira Pharma, Inc. (ATHA); Lead Plaintiff Deadline is August 24, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - July 2, 2021) - Berger Montague is investigating securities fraud allegations against Athira Pharma, Inc. ("Athira" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Athira securities (NASDAQ: ATHA) between September 18, 2020 and June 17, 2021 (the "Class Period"), including shares purchased on or traceable to the Company's initial public offering in September 2020. If you purchased Athira securities during the Class Period, would...
- 07/02/2021
|
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Athira Pharma, Inc. Investors to Secure Counsel Before Important August 24 Deadline in Securities Class Action – ATHA
- NEW YORK--(BUSINESS WIRE)-- #ATHA--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of class action lawsuits on behalf of purchasers of the securities of Athira Pharma, Inc. (NASDAQ: ATHA): (a) pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the “IPO” or “Offering”); and/or (b) between September 18, 2020 and June 17, 2021, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to s
- 07/02/2021
|
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 2, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 07/02/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athira Pharma, Inc. - ATHA
- NEW YORK, July 1, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of. Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA).
- 07/01/2021
|
Athira Class Action Reminder
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - July 1, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) and reminds investors of the August 24, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Athira stock purchased pursuant...
- 07/01/2021
|
ATHIRA PHARMA, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Western District of Washington against Athira Pharma, Inc.
- NEW YORK, July 1, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Western District of Washington on behalf of investors that purchased Athira Pharma, Inc. ("Athira" orthe "Company") (NASDAQ: ATHA) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's September 2020 initial public offering ("IPO" or the "Offering") at $17.00 share. All investors who purchased Athira Pharma, Inc. and incurred losses are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774.
- 07/01/2021
|
SHAREHOLDER ALERT: Robbins LLP Announces that Athira Pharam, Inc. (ATHA) is Being Sued for Misleading Shareholders
- SAN DIEGO & BOTHELL, Wash.--(BUSINESS WIRE)---- $ATHA #ATHA--Shareholder rights law firm Robbins LLP announces that several class actions have been filed on behalf of all purchasers of Athira Pharma, Inc. (NASDAQ: ATHA) who acquired Athira securities between September 18, 2020 and June 17, 2021. The complaint asserts claims under the Securities Exchange Act of 1934. Athira is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration f
- 07/01/2021
|
ATHA Stock: Berger Montague Investigates Securities Fraud Claims Against Athira Pharma, Inc. (ATHA); Lead Plaintiff Deadline is August 24, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - July 1, 2021) - Berger Montague is investigating securities fraud allegations against Athira Pharma, Inc. ("Athira" or the "Company") on behalf of investors who purchased Athira securities (NASDAQ: ATHA) between September 18, 2020 and June 17, 2021 (the "Class Period"), including shares purchased on or traceable to the Company's initial public offering in September 2020.If you purchased Athira securities during the Class Period, have questions concerning your rights or interests, or...
- 07/01/2021
|
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - July 1, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 07/01/2021
|
Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Athira Pharma, Inc. - ATHA
- RADNOR, Pa., June 30, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that securities fraud class action lawsuits have been filed against Athira Pharma, Inc. (NASDAQ: ATHA) ("Athira") on behalf of those who purchased or acquired Athira common stock: a) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Athira's September 2020 initial public offering ("IPO"); and/or b) between September 18, 2020 and June 17, 2021 , inclusive (the "Class Period").
- 06/30/2021
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $ATHA #ATHA--SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc.
- 06/30/2021
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Athira Pharma, Inc. (ATHA) Investors
- LOS ANGELES--(BUSINESS WIRE)---- $ATHA #investors--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Athira Pharma, Inc. (ATHA) Investors
- 06/30/2021
|
Athira Pharma - ATH-1017: Panacea Or Pandora's Box?
- Athira shares plunged over 39% on June 18 after founder/CEO Leen Kawas was placed on temporary leave due to an ongoing review into her doctoral research at Washington State University. The review is examining potential misconduct stemming from allegations of altered images in her doctoral dissertation and several other research papers published from 2011-2012.
- 06/30/2021
|
ATHA INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Athira Pharma, Inc.
- NEW YORK, June 30, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a Lead Plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) from September 18, 2020 through June 17, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the Western District of Washington alleges violations of the Exchange Act of 1934.
- 06/30/2021
|
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Athira Pharma, Inc. Investors with Losses Over $100K to Secure Counsel Before Important August 24 Deadline - ATHA
- NEW YORK, June 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of class action lawsuits on behalf of purchasers of the securities of Athira Pharma, Inc. (NASDAQ: ATHA): (a) pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO" or "Offering"); and/or (b) between September 18, 2020 and June 17, 2021, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
- 06/29/2021
|
Athira Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - June 29, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ:ATHA) and reminds investors of the August 24, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Athira stock purchased pursuant and/or...
- 06/29/2021
|
Keller Rohrback Files Suit Against Athira Pharma for Misrepresentations in IPO Registration Statement
- SEATTLE--(BUSINESS WIRE)--Keller Rohrback filed a lawsuit against Athira Pharma, certain of its officers and directors, and the underwriters of the IPO of Athira common stock.
- 06/29/2021
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 29, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...
- 06/29/2021
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athira Pharma, Inc. (ATHA)
- LOS ANGELES--(BUSINESS WIRE)---- $ATHA #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 24, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Athira Pharma, Inc. (“Athira” or the “Company”) (NASDAQ: ATHA): (a) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company's September 2020 i
- 06/29/2021
|
Biotech firm Athira Pharma hit by class action lawsuits following image manipulation claims
- The lawsuits have begun.
- 06/29/2021
|
ATHA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Athira Pharma, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm
- NEW YORK, June 29, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Athira Pharma, Inc. ("Athira " or "the Company") (NASDAQ: ATHA) on behalf of shareholders who purchased or otherwise acquired Athira common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's September 2020 initial public offering ("IPO" or the "Offering"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/atha.
- 06/29/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Athira Pharma (ATHA) Investors to Contact Firm's Attorneys Now, Securities Fraud Case Filed
- SAN FRANCISCO, June 28, 2021 /PRNewswire/ -- Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims.
- 06/28/2021
|
ATHIRA ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Athira Pharma, Inc. and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Western District of Washington on behalf of investors that purchased Athira Pharma, Inc. (NASDAQ: ATHA) common stock pursuant and/or traceable to the Company's initial public offering conducted on or about September 2020 (the “IPO” or “Offering”). Investors have until August 24, 2021 to a
- 06/28/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $ATHA #ATHA--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc.
- 06/28/2021
|
EQUITY ALERT: Rosen Law Firm Encourages Athira Pharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – ATHA
- NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of class action lawsuits on behalf of purchasers of the securities of Athira Pharma, Inc. (NASDAQ: ATHA): (a) pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the “IPO” or “Offering”); or (b) between September 18, 2020 and June 17, 2021, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve
- 06/28/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athira Pharma, Inc. - ATHA
- New York, New York--(Newsfile Corp. - June 28, 2021) - Pomerantz LLP is investigating claims on behalf of investors of. Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Athira and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 06/28/2021
|
Notice of Lead Plaintiff Deadline for Shareholders in the Athira Pharma, Inc. Class Action Lawsuit – ATHA
- SAN DIEGO--(BUSINESS WIRE)-- #ATHAHstock--The suit alleges defendants issued false statements concerning Athira business and prospects, resulting in its stock trading at inflated prices.
- 06/28/2021
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Athira Pharma, Inc. (ATHA) Investors
- BENSALEM, Pa.--(BUSINESS WIRE)---- $ATHA #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Athira Pharma, Inc. (“Athira” or the “Company”) (NASDAQ: ATHA) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company's September 2020 initial public offering (“IPO” or the “Offering”). Athira investors have until August 24, 2021 to f
- 06/28/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athira Pharma, Inc. - ATHA
- New York, New York--(Newsfile Corp. - June 27, 2021) - Pomerantz LLP is investigating claims on behalf of investors of. Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Athira and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 06/27/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athira Pharma, Inc. - ATHA
- New York, New York--(Newsfile Corp. - June 26, 2021) - Pomerantz LLP is investigating claims on behalf of investors of. Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Athira and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 06/26/2021
|
ATHA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Athira Pharma, Inc.
- LOS ANGELES--(BUSINESS WIRE)---- $ATHA #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Western District of Washington captioned Jawandha v. Athira Pharma, Inc., et al., (Case No. 21-cv-862) on behalf of persons and entities that purchased or otherwise acquired Athira Pharma, Inc. (“Athira” or the “Company”) (NASDAQ: ATHA) common stock pursuant and/or traceable to the registration statement and prospectus (collectively
- 06/25/2021
|
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Athira Pharma, Inc. and Encourages Investors with Losses to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 24, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. On June 17, 2021, Athira released a statement indicating it had...
- 06/24/2021
|
Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Athira Pharma, Inc. (ATHA) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $ATHA #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of Athira Pharma, Inc. (“Athira” or the “Company”) (NASDAQ: ATHA) investors concerning the Company and its officers' possible violations of the federal securities laws. If you suffered a loss on your Athira investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your
- 06/23/2021
|
The Law Offices of Frank R. Cruz Continues Investigation of Athira Pharma, Inc. (ATHA) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $ATHA #investors--The Law Offices of Frank R. Cruz Continues Investigation of Athira Pharma, Inc. (ATHA) on Behalf of Investors
- 06/23/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Athira Pharma (ATHA) Investors to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations
- SAN FRANCISCO, June 23, 2021 /PRNewswire/ -- Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations related to Athira's recent decision to place its CEO (Leen Kawas) on temporary leave.
- 06/23/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Athira Pharma (ATHA) Investors to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations
- San Francisco, California--(Newsfile Corp. - June 22, 2021) - Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations related to Athira's recent decision to place its CEO (Leen Kawas) on temporary leave. Visit: www.hbsslaw.com/investor-fraud/ATHA Contact An Attorney Now: ATHA@hbsslaw.com 844-916-0895Athira Pharma, Inc. (ATHA) Investigation:The investigation focuses on matters prompting Athira's...
- 06/22/2021
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Athira Pharma, Inc. (ATHA) on Behalf of Investors
- BENSALEM, Pa.--(BUSINESS WIRE)---- $ATHA #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Athira Pharma, Inc. (“Athira” or the “Company”) (NASDAQ: ATHA) investors concerning the Company's possible violations of federal securities laws. On June 17, 2021, after the market closed, Athira announced that it had placed its president and Chief Executive Officer, Leen Kawas, on leave pending a review of actions stemming from doctoral research Dr. Kawas conducted while at Washington State U
- 06/22/2021
|
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Athira Pharma, Inc. and Encourages Investors with Losses to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 22, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. On June 17, 2021, Athira released a statement indicating it had...
- 06/22/2021
|
ATHIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Athira Pharma, Inc. on Behalf of Athira Stockholders and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Athira Pharma, Inc. (NASDAQ: ATHA) on behalf of Athira stockholders. Our investigation concerns whether Athira has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On September 22, 2020, the Company closed its initial public offering, in which the Company sold a
- 06/21/2021
|
Lost Money in Athira Pharma, Inc.?
- OAKLAND, Calif.--(BUSINESS WIRE)---- $ATHA #ATHA--Gibbs Law Group investigates potential legal claims on behalf of Athira Pharma investors.
- 06/21/2021
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Athira Pharma, Inc. (ATHA) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $ATHA #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Athira Pharma, Inc. (“Athira” or the “Company”) (NASDAQ: ATHA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Athira investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities law
- 06/21/2021
|
The Law Offices of Frank R. Cruz Announces Investigation of Athira Pharma, Inc. (ATHA) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $ATHA #investors--The Law Offices of Frank R. Cruz Announces Investigation of Athira Pharma, Inc. (ATHA) on Behalf of Investors
- 06/21/2021
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Athira Pharma, Inc. (ATHA) on Behalf of Investors
- BENSALEM, Pa.--(BUSINESS WIRE)---- $ATHA #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Athira Pharma, Inc. (“Athira” or the “Company”) (NASDAQ: ATHA) investors concerning the Company's possible violations of federal securities laws. On June 17, 2021, after the market closed, Athira announced that it had placed its president and Chief Executive Officer, Leen Kawas, on leave pending a review of actions stemming from doctoral research Dr. Kawas conducted while at Washington State U
- 06/21/2021
|
Implied Volatility Surging for Athira Pharma (ATHA) Stock Options
- Investors need to pay close attention to Athira Pharma (ATHA) stock based on the movements in the options market lately.
- 06/21/2021
|
Ademi LLP Investigates Claims of Securities Fraud against Athira Pharma, Inc.
- MILWAUKEE, June 21, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Athira (NASDAQ: ATHA). The investigation results from inaccurate statements Athira may have made regarding its business operations and prospects.
- 06/21/2021
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Athira Pharma, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $ATHA #ATHA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Athira Pharma, Inc.
- 06/18/2021
|
Why Athira Pharma Crashed Today
- There was a big shakeup in the biotech's C-suite.
- 06/18/2021
|
Washington State University to review claims of research misconduct
- PULLMAN, Wash., June 18, 2021 /PRNewswire/ -- Washington State University announced today that it has undertaken a review of claims of potential research misconduct involving research conducted by Leen Kawas, a former WSU student and current president and chief executive officer of Athira Pharma, Inc. (NASDAQ: ATHA).
- 06/18/2021
|
Wolf Popper LLP Announces Investigation on Behalf of Purchasers of Athira Pharma, Inc. (ATHA) Common Stock
- New York, New York--(Newsfile Corp. - June 18, 2021) - Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Athira Pharma, Inc. (NASDAQ: ATHA) common stock.Athira is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. Athira's lead drug candidate is ATH-1017 which is used to treat Alzheimer's and Parkinson's dementia. Athira conducted an initial public offering of its common...
- 06/18/2021
|
Berman Tabacco Investigates Potential Securities Claims Against Athira Pharma, Inc. (ATHA)
- Boston, Massachusetts--(Newsfile Corp. - June 18, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential violations of the federal securities laws by Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA). Athira, formerly known as M3 Biotechnology, Inc., is a biopharmaceutical company based in Bothell, Washington. On September 22, 2020, the Company closed its initial public offering, in which the Company sold and issued 12,000,000 shares of common stock...
- 06/18/2021
|
Athira Pharma Stock Plummets After CEO Placed On Temporary Leave
- Athira Pharma Inc (NASDAQ: ATHA) CEO Leen Kawas has been placed on temporary leave until the company completes a review “stemming from doctoral research Dr. Kawas conducted while at Washington State University.” The 10-year-old company, which is developing drugs for treating Alzheimer's disease, said that Chief Operating Officer Mark Litton would assume day-to-day responsibilities during Kawas' leave.
- 06/18/2021
|
ATHA Stock Price Falls Over 25% Pre-Market: Why It Happened
- The stock price of Athira Pharma Inc (NASDAQ: ATHA) fell by over 25% pre-market. This is why it happened.
- 06/18/2021
|
Athira Pharma CEO placed on leave, shares plummet
- Athira Pharma CEO Leen Kawas has been placed on temporary leave until the Seattle area biotechnology company completes a review “stemming from doctoral research Dr.
- 06/17/2021
|
Athira Pharma Chief Operating Officer, Mark Litton, Assumes Day-to-Day Leadership Responsibilities of Company
- Leen Kawas Placed on Temporary Leave Pending Board Review of Actions Stemming from Doctoral Research while at Washington State University Leen Kawas Placed on Temporary Leave Pending Board Review of Actions Stemming from Doctoral Research while at Washington State University
- 06/17/2021
|
Athira Pharma to Present at Upcoming Investor Conferences
- – JMP Securities Life Sciences Conference
- 06/09/2021
|
Approval of Biogen's drug for Alzheimer's disease may ease path for others such as Athira Pharma
- The approval on Monday of the first new drug for Alzheimer's disease in nearly two decades — Biogen's aducanumab — helps shine a light on a path forward for other companies developing Alzheimer's therapies, including Seattle-based Athira Pharma, which saw its stock rise more than 4% off the Biogen news.
- 06/07/2021
|
Athira Pharma Reports First Quarter 2021 Financial Results and Provides Business Highlights
- -Phase 2 trial initiation for Parkinson's disease dementia program and IND submission for neuropsychiatric program planned by end of 2021-
- 05/13/2021
|
Athira Pharma, Inc. (ATHA) Upgraded to Buy: Here's What You Should Know
- Athira Pharma, Inc. (ATHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 04/22/2021
|
Athira Pharma to Participate in Panel Discussion at Sachs 4th Annual Neuroscience Innovation Forum
- BOTHELL, Wash., April 21, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executive Officer, will participate in a virtual panel discussion at the Sachs 4th Annual Neuroscience Innovation Forum. The panel, titled “Progress in Alzheimer's and Dementia,” will be aired on Wednesday, April 28, 2021, at 8:30 a.m. PT /11:30 a.m. ET.
- 04/21/2021
|
Athira Pharma to Host Educational Webinar on Targeting HGF/MET: A Naturally Occurring Neuronal Repair Pathway
- BOTHELL, Wash., April 08, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that it will host an educational webinar on targeting HGF/MET, a naturally occurring, neuronal repair pathway. The live webinar event will be on Thursday, April 15, at 1:30 p.m. PT / 4:30 p.m.ET.
- 04/08/2021
|
Athira Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
- – LIFT-AD and ACT-AD studies evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer's disease, actively enrolling patients –
- 03/25/2021
|
Athira Pharma to Present at Stifel's 3rd Annual CNS Conference
- BOTHELL, Wash., March 24, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at Stifel's 3rd Annual CNS Conference on Thursday, April 1, 2021, at 9:00 am ET.
- 03/24/2021
|
U.S. IPO Week Ahead: The Spring IPO Market Starts To Thaw In An 8 IPO Week
- The IPO market starts to pick back up with eight IPOs scheduled to raise $2.2 billion in the week ahead. Street research is expected for one company on Sunday, 3/14.
- 03/13/2021
|
Athira Pharma to Present at H.C. Wainwright & Co. Global Life Sciences Conference
- BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executive Officer, will present a corporate overview during the H.C. Wainwright & Co. Global Life Sciences Conference. A pre-recorded presentation will be available for on-demand viewing beginning at 7:00 am ET on Tuesday, March 9, 2021.
- 03/02/2021
|
3 Net-Net Working Capital Stocks
- There are some investors who purchase stocks that are trading below their liquidation value because they believe they can make impressive gains out of their investments after the market has reassessed the share prices near or above the liquidation value. Should the company fail, these shareholders would, in theory, still be able to make money due to a difference between the liquidation value and purchasing price.
- 02/16/2021
|
Athira Pharma Announces Exercise of Underwriters' Option to Purchase Additional Shares
- BOTHELL, Wash., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that the underwriters of its public offering have exercised in full their option to purchase an additional 600,000 shares of common stock at the public offering price of $22.50 per share, less underwriting discounts and commissions. Including proceeds from the sale of the additional shares, Athira received total gross proceeds of $103.5 million from the public offering, before deducting underwriting discounts and commissions and other offering expenses payable by Athira. The closing of the sale of the additional shares occurred today.
- 02/10/2021
|
Notable Insider Buys Seen In The Past Week: Green Brick, Intel, Teledyne And More
- Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets.
- 01/30/2021
|
Why Athira Pharma Stock Dropped Today
- The clinical-stage biopharma company announced the pricing of a public stock offering.
- 01/21/2021
|
Athira Pharma Announces Pricing of Public Offering of Common Stock
- BOTHELL, Wash., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $22.50 per share. All of the shares of common stock are being offered by Athira. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Athira, are expected to be $90.0 million. The offering is expected to close on January 25, 2021, subject to satisfaction of customary closing conditions. In addition, Athira has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock at the public offering price less underwriting discounts and commissions.
- 01/20/2021
|
Athira Pharma Announces Proposed Public Offering of Common Stock
- BOTHELL, Wash., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. All of the shares in the proposed offering will be sold by Athira. In addition, Athira expects to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering.
- 01/19/2021
|
Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach
- Athira is a recent IPO with early but interesting data in AD. They will provide data from a potentially pivotal phase 2/3 trial in end-2022.
- 01/11/2021
|
Athira Pharma to Present at the 39th Annual J.P. Morgan Healthcare Conference
- SEATTLE, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executive Officer, will present a company overview and pipeline update at the 39th Annual J.P. Morgan Conference, being held virtually, on Thursday, January 14, 2021 at 2:50 p.m. ET.
- 01/07/2021
|
Athira Pharma Announces Appointment of Kelly A. Romano to its Board of Directors
- SEATTLE, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Kelly A. Romano to its Board of Directors. Ms. Romano is the Founder and Chief Executive Officer of BlueRipple Capital, LLC, a consultancy firm for global technology companies.
- 12/14/2020
|
Athira Pharma wins $15M grant for clinical trial of Alzheimer's drug from National Institute on Aging
- Seattle-based biotech company Athira Pharma announced a three-year grant totaling $15 million from the National Institute on Aging to support an upcoming clinical trial of a treatment that seeks to stop the deterioration of neurons and restore healthy brain activity in people with mild to moderate cases of Alzheimer's disease.
- 12/08/2020
|
Athira Pharma Awarded $15 Million Grant from National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimer's Disease
- SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced it has been awarded a research grant expected to total $15 million over 3 years from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) to support its ACT-AD Phase 2 clinical trial for ATH-1017, Athira's lead therapeutic candidate being developed for the treatment of individuals with mild-to-moderate Alzheimer's disease.
- 12/08/2020
|
Athira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of Mild-to-Moderate Alzheimer's Disease
- SEATTLE, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that patient dosing has begun in ACT-AD, a Phase 2 randomized, placebo-controlled study of ATH-1017 in patients with mild-to-moderate Alzheimer's disease. ATH-1017 is a small molecule therapeutic designed to enhance the activity of Hepatocyte Growth Factor (HGF) and its receptor, MET, which are expressed in the central nervous system, in order to promote brain health and function.
- 12/01/2020
|
Athira Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights
- - LIFT-AD clinical trial evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer's disease, actively enrolling
- 11/12/2020
|
Athira Pharma to Present at Upcoming November Investor Conferences
- SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Dr. Leen Kawas, President and Chief Executive Officer, and Dr. Hans Moebius, Chief Medical Officer, will participate in fireside chats at two upcoming investor conferences:
- 11/10/2020
|
Athira Pharma Seeks $160 Million To Advance Alzheimer's Treatment
- Athira Pharma has filed proposed terms for its $160 million IPO. The firm is developing treatments for Alzheimer's and Parkinson's diseases and other neurological conditions.
- 09/14/2020
|
